See more : Sesoda Corporation (1708.TW) Income Statement Analysis – Financial Results
Complete financial analysis of EV Biologics, Inc. (YECO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EV Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Beijing Yuanlong Yato Culture Dissemination Co.,Ltd. (002878.SZ) Income Statement Analysis – Financial Results
- China Environmental Technology Holdings Limited (0646.HK) Income Statement Analysis – Financial Results
- Emerson Electric Co. (EMR) Income Statement Analysis – Financial Results
- Fuji P.S Corporation (1848.T) Income Statement Analysis – Financial Results
- Silvergate Capital Corporation (SI-PA) Income Statement Analysis – Financial Results
EV Biologics, Inc. (YECO)
About EV Biologics, Inc.
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.90K | 0.00 | 118.90K | 0.00 | 0.00 | 9.47M | 42.64M | 46.23M | 44.46M | 42.48M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.94M | 26.17M | 29.36M | 27.50M | 26.78M |
| Gross Profit | 48.90K | 0.00 | 118.90K | 0.00 | 0.00 | 1.54M | 16.48M | 16.87M | 16.95M | 15.70M |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 16.24% | 38.64% | 36.49% | 38.13% | 36.95% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 759.22K | 12.84M | 3.37M | 806.04K | 711.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 624.68K | 451.93K | 634.39K | 930.47K | 869.30K |
| SG&A | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 1.38M | 13.29M | 4.01M | 1.74M | 1.58M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -102.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 1.38M | 13.29M | 4.01M | 1.74M | 1.58M |
| Cost & Expenses | 531.96K | 590.04K | 143.16K | 98.96K | 98.40K | 9.32M | 39.46M | 33.37M | 29.24M | 28.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.33K | 70.07K | 18.19K | 3.61K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.38K | 1.04M | 1.30M | 1.18M | 1.15M |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 687.00K | 2.22M | 1.77M | 1.39M | 1.05M |
| EBITDA | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -6.64M | -5.82M | -46.57M | 14.63M | 16.54M |
| EBITDA Ratio | -2,591.27% | 0.00% | -20.40% | 0.00% | 0.00% | 7.80% | 12.91% | 31.64% | 37.35% | 35.70% |
| Operating Income | -483.06K | -590.04K | -24.26K | -98.96K | -98.40K | 52.40K | 3.29M | 12.86M | 15.22M | 14.12M |
| Operating Income Ratio | -987.86% | 0.00% | -20.40% | 0.00% | 0.00% | 0.55% | 7.71% | 27.81% | 34.23% | 33.23% |
| Total Other Income/Expenses | -784.07K | -20.47M | -363.44K | -1.00 | -3.00 | -678.84K | -1.32M | -332.56K | -1.28M | -1.27M |
| Income Before Tax | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -523.99K | -49.83M | 11.58M | 13.95M | 12.96M |
| Income Before Tax Ratio | -2,591.28% | 0.00% | -326.07% | 0.00% | 0.00% | -5.53% | -116.86% | 25.04% | 31.38% | 30.50% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | 27.59K | 3.36M | 2.90M | 3.26M | 2.91M |
| Net Income | -1.27M | -21.06M | -387.70K | -98.96K | -98.40K | -551.58K | -53.19M | 8.68M | 10.69M | 10.05M |
| Net Income Ratio | -2,591.28% | 0.00% | -326.07% | 0.00% | 0.00% | -5.82% | -124.73% | 18.77% | 24.05% | 23.66% |
| EPS | -0.12 | -2.91 | -0.05 | -0.01 | -0.02 | 0.00 | -22.30 | 5.40 | 6.94 | 5.24 |
| EPS Diluted | -0.12 | -2.91 | -0.05 | -0.01 | -0.02 | 0.00 | -22.30 | 5.40 | 6.94 | 5.24 |
| Weighted Avg Shares Out | 10.23M | 7.23M | 7.23M | 7.23M | 6.43M | 2.41M | 2.39M | 1.60M | 1.53M | 1.92M |
| Weighted Avg Shares Out (Dil) | 10.23M | 7.23M | 7.23M | 7.23M | 6.43M | 2.41M | 2.39M | 1.60M | 1.53M | 1.92M |
EV Biologics Updates on Funding and Sales
TAMPA, FL / ACCESSWIRE / October 2, 2023 / EV Biologics Corp, (OTC Pink:YECO), today announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other...
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product. Rigorous product analysis has already begun, and the Company has engaged...
EV Biologics Appoints Senior Investment Banker as Corporate Finance Director
TAMPA, FL / ACCESSWIRE / August 7, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has appointed William Bossung as Corporate Finance Director. Mr. Bossung brings a wealth of experience as a long-time investment banker, with 5...
EV Biologics Hires Senior Chief Financial Officer
TAMPA, FL / ACCESSWIRE / August 2, 2023 / EV Biologics Corp (OTC PINK:YECO) today announced that it has hired Monte Fisher as Chief Financial Officer. Mr. Fisher brings a wealth of experience as a long-time senior employee of Shell...
EV Biologics Updates on NFT Minting
NASHVILLE, TN / ACCESSWIRE / September 28, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT and minting progress. Our NFT team has been minting the NFT, designated rEVerie, on the Ghostmarket.io platform,...
EV Biologics Updates on NFT Warrant Dividend Distribution
NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution. The Company is currently finalizing its filing with FINRA, and then will have its...
EV Biologics Briefs Shareholders on Market Cap Peer Comparison
NASHVILLE, TN / ACCESSWIRE / August 12, 2021 / EV Biologics Corp, OTC Pink:YECO, today briefed shareholders on its current value compared to other public biotechnology companies in its peer group. Please view the chart at: https://www.evbiologics.com/marketcap/.
EV Biologics NFT Dividend Information
NASHVILLE, TN / ACCESSWIRE / August 9, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT Warrant Dividend. Attached is a preliminary image from the 3D animation still under development that will be...
EV Biologics NFT Dividend Warrant Date
NASHVILLE, TN / ACCESSWIRE / July 30, 2021 / EV Biologics Corp., OTC PINK:YECO, today confirmed for share holders its NFT Warrant Dividend shareholders-of-record date. YECO's shareholders-of-record on July 30, 2021 will receive the Warrant.
EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services
NASHVILLE, TN / ACCESSWIRE / July 28, 2021 / EV Biologics Corp, OTC PINK:YECO today announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master...
Source: https://incomestatements.info
Category: Stock Reports